Prism Medico and Pharmacy Ltd has reported a net profit of Rs 0.23 crore for the quarter ended September 30, 2026, marking a successful turnaround from losses in the previous two quarters. The company's total income reached Rs 0.45 crore, up from Rs 0.09 crore in the June quarter. While the firm shows improved profitability and a significant cash inflow from recent capital raising, investors are advised to watch for revenue consistency and the strategic deployment of these new funds.
Prism Medico Returns to Profitability in Q2 FY27
Prism Medico and Pharmacy Ltd recorded a net profit of Rs 0.23 crore for the quarter ending September 30, 2026. Total income for the same period stood at Rs 0.45 crore, reflecting a recovery from the previous quarter's low.
Reader Takeaway: The firm returned to profit, but revenue remains below year-ago levels, necessitating monitoring of long-term consistency.
What just happened
Prism Medico and Pharmacy Ltd released its standalone financial results for the quarter ended September 30, 2026, which were approved by the Board on November 5, 2026. The company reported a net profit of Rs 0.23 crore, reversing the losses of Rs 0.06 crore reported in the June 2026 quarter and Rs 0.08 crore in the September 2025 quarter. Total income increased sequentially to Rs 0.45 crore from Rs 0.09 crore, though it remains lower than the Rs 0.52 crore recorded in the corresponding period last year.
Why this matters
The transition from a loss-making trajectory to profit is a key indicator of potential operational recovery. The Basic and Diluted EPS for the quarter improved to 0.0017, providing a positive shift from the negative EPS seen in the preceding two quarters.
The backstory
The company faced consecutive losses in the June 2026 and September 2025 quarters. This latest financial statement confirms the Board’s focus on stabilizing performance. The statutory audit was conducted by Garg Mendiratta & Associates, confirming the results align with regulatory filings.
What changes now
The company’s balance sheet reflects a significant cash flow increase, with a net increase in cash and equivalents of Rs 16.56 crore for the half-year. This was largely driven by proceeds from the issuance of share capital and warrants. Investors should look for management’s guidance on how these funds will be deployed to support core business operations.
What to track next
Key metrics for investors to monitor include the sustainability of this profitability, future revenue growth trends, and the operational impact of the recent capital infusion.